TSC-202 / TSCan Therap - LARVOL DELTA

TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=840 | Recruiting | Sponsor: TScan Therapeutics, Inc. | N=100 ➔ 840

Enrollment change • Anal Carcinoma • Cervical Adenocarcinoma • Cervical Cancer • Colorectal Cancer • Cutaneous Melanoma • Head and Neck Cancer • Infectious Disease • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Oropharyngeal Cancer • Ovarian Cancer • Penile Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Vaginal Cancer • Vulvar Cancer • HLA-A • HLA-C • PRAME

Discovery of a MAGE-A4-specific TCR-T therapy candidate for multiplex treatment of solid tumors (SITC 2024) - "MAGE-A4-specific TCR-T cells also displayed in vivo efficacy in reducing tumor burden in xenograft mouse models. Conclusions The autologous MAGE-A4-specific TCR-T therapy candidate TSC-202-A0201 has been advanced to IND-enabling studies to be added to TScan's Immunobank of TCRs, with the ultimate goal of being used in a multiplex approach known as T-Plex as a best-in-class immunotherapy strategy for treating patients with solid tumors."

IO biomarker • Colon Cancer • Colorectal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • MAGEA4

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire) - "TScan Therapeutics, Inc...today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually."

Preclinical • Oncology • Solid Tumor

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities (GlobeNewswire) - "Initiate Phase 1 umbrella trial for TSC-100 following submission of clinical protocol to IRBs for the initial study sites, with plans to enroll patients in the first half of 2022...Progress IND-enabling studies for the TSC-200 series and submit two IND applications during the second half of 2022. These are expected to include TSC-200 for HPV and TSC-204 for MAGE-A1; In 2023, the Company plans to release initial clinical data for the TSC-200 series TCRs, as well as file further INDs for additional programs in this series."

Clinical data • IND • New P1 trial • Hematological Malignancies • Oncology • Solid Tumor

TScan Outlines 2022 Priorities as Programs Enter Clinic (GlobeNewswire) - "Following the IND submissions and pending acceptance by the FDA, the Company expects to initiate Phase 1 clinical trials for TSC-100 and TSC-101 in the first half of 2022, with preliminary data expected in the second half of 2022....TScan plans to present initial preclinical data on the TSC-2xx series at a medical meeting in the first half of 2022. TScan plans to progress IND-enabling studies for the TSC-2xx series and submit multiple IND applications during the second half of 2022."

IND • New P1 trial • P1 data • Preclinical • Hematological Malignancies • Oncology • Solid Tumor

TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies (GlobeNewswire) - "TScan Therapeutics...announced that it has completed the construction of a state-of-the-art GMP manufacturing facility to manufacture Phase I/II TCR-T therapies. This facility will support the manufacturing of TScan’s two lead liquid tumor candidates, TSC-100 and TSC-101, designed to eliminate residual leukemia and prevent relapse after hematopoietic cell transplantation for patients with hematological malignancies, as well as solid tumor candidates TSC-200, TSC-201, TSC-202 and TSC-203, designed to treat patients with solid tumors including head and neck, cervical, anal, melanoma and non-small cell lung cancers."

Commercial • Anal Carcinoma • Cervical Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor